螺内酯与ACEI、β受体阻滞剂联合治疗慢性心力衰竭患者中作用与疗效观察
详细信息 查看官网全文
- 论文作者：刘阳
- 年：2016
- 作者机构：北京航天中心医院老年科;
- 论文关键词：螺内酯 ; ACEI ; β受体阻滞剂 ; 慢性心力衰竭
- 英文论文关键词：ACEI ; spironolactone ; beta blockers ; chronic heart failure
- 会议召开时间：2016-11-25
- 会议录名称：湖南中医药大学学报2016/专集：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会论文集
- 语种：中文
- 分类号：R541.6
- 学会代码：HNZY
- 会议名称：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会
- 会议地点：中国广东珠海
- 主办单位：国际数字医学会、Digital Chinese Medicine
- 学会名称：湖南中医药大学期刊杂志社
- 页数：1
- 文件大小：1807k
- 原文格式：D
- 会议级别：全国
摘要
目的:探究螺内酯与ACEI、β受体阻滞剂联合治疗在慢性心力衰竭临床治疗中的应用价值。方法:选择我院2011年1月-2015年5月收治的72例慢性心力衰竭患者,根据患者治疗方法的不同随机分为对照组和观察组,比较两组患者的临床治疗效果,治疗1年后进行随访调查两组患者的左心室舒张末期收缩内径、左心室射血分数及心血管事件的发生情况。结果:对照组临床治疗总有效率77.78%,观察组91.67%,观察组患者的临床治疗总有效率显著高于对照组患者(P<0.05),具有统计学意义;观察组患者治疗1年后左心室舒张末期收缩内径(48.41±6.94)mm、左心室射血分数(63.18±7.25)%、心血管不良事件发生率为8.33%,两组患者的预后情况上存在显著性差异(P<0.05),具有统计学意义。结论:螺内酯与ACEI、β受体阻滞剂联合治疗慢性心力衰竭疗效确切,有效该患者心功能,提高临床治疗效率,预后良好,具有良好的安全性和稳定性,值得在临床上推广应用。
Objective: To explore the ACEI, beta blockers and spironolactone combination therapy clinical value in treatment of chronic heart failure. Methods: 72 cases of chronicheart failure patients in our hospital in January 2011-2013 year in May, according to the different treatment methods were randomly divided into control group and observation group, comparedtwo groups of patients with clinical curative effect, the treatment after 3 year follow-up survey of two groups of patients with left ventricular end diastolic diameter and left ventricular contractionejection fraction and cardiovascular events. Results: the clinical treatment of the control group the total efficiency of 77.78%, 91.67% in the observation group, clinical observation of patients inthe treatment group the total effective rate was significantly higher than that of the control group(P < 0.05), with statistical significance; the patients in the observation group left ventricular enddiastolic systolic diameter after 3 years(48.41 + 6.94) mm, left ventricular ejection fraction(63.18 + 7.25)%, the incidence rate of cardiovascular events was 8.33%, there was significant difference onthe prognosis in the patients of the two groups(P < 0.05), with statistical significance. Conclusion: ACEI, spironolactone and beta blocker combinations in the treatment of chronic heart failure iseffective, effective the cardiac function of the patients, improve the clinical efficiency of treatment, the prognosis is good, with good safety and stability, it is worthy of clinical application.
Objective: To explore the ACEI, beta blockers and spironolactone combination therapy clinical value in treatment of chronic heart failure. Methods: 72 cases of chronicheart failure patients in our hospital in January 2011-2013 year in May, according to the different treatment methods were randomly divided into control group and observation group, comparedtwo groups of patients with clinical curative effect, the treatment after 3 year follow-up survey of two groups of patients with left ventricular end diastolic diameter and left ventricular contractionejection fraction and cardiovascular events. Results: the clinical treatment of the control group the total efficiency of 77.78%, 91.67% in the observation group, clinical observation of patients inthe treatment group the total effective rate was significantly higher than that of the control group(P < 0.05), with statistical significance; the patients in the observation group left ventricular enddiastolic systolic diameter after 3 years(48.41 + 6.94) mm, left ventricular ejection fraction(63.18 + 7.25)%, the incidence rate of cardiovascular events was 8.33%, there was significant difference onthe prognosis in the patients of the two groups(P < 0.05), with statistical significance. Conclusion: ACEI, spironolactone and beta blocker combinations in the treatment of chronic heart failure iseffective, effective the cardiac function of the patients, improve the clinical efficiency of treatment, the prognosis is good, with good safety and stability, it is worthy of clinical application.
引文
[1]何绍堂.ACEI与β受体阻滞剂联合治疗慢性心力衰竭患者的疗效观察[J].中国医药指南,2014,(10):135-136.
[2]冯颖青,李勇,张宇清等.β受体阻滞剂在高血压应用中的专家指导建议[J].中国医学前沿杂志,2013,(04):58-66.
[3]戴士鹏,李瑞霞,张建刚,耿涛,徐泽升.螺内酯对老年收缩性心力衰竭患者心室重构和安全性研究[J].实用老年医学,2013,(08):666-669.
[4]王文.β受体阻滞剂在高血压治疗中的地位和再评价[J].中华高血压杂志,2013,(08):715-718.
[5]冯颖青,李勇,张宇清等.β受体阻滞剂在高血压应用中的专家指导建议[J].中华高血压杂志,2013,(08):719-727.
[6]李露,常静.β受体阻滞剂预防心力衰竭患者心脏性猝死的研究进展[J].重庆医学,2012,1(7):1768-1771.
[7]冯颖青,李勇,张宇清,王浩,陈源源,孙忠实,李悦,王鸿懿,孙宁玲.β受体阻滞剂在高血压应用中的专家指导建议[J].慢性病学杂志,2013,1(1):806-815.
[8]郭艺芳.β受体阻滞剂是否可以常规用于所有冠状动脉性心脏病患者[J].中华高血压杂志,2015,(02):109-114.
[2]冯颖青,李勇,张宇清等.β受体阻滞剂在高血压应用中的专家指导建议[J].中国医学前沿杂志,2013,(04):58-66.
[3]戴士鹏,李瑞霞,张建刚,耿涛,徐泽升.螺内酯对老年收缩性心力衰竭患者心室重构和安全性研究[J].实用老年医学,2013,(08):666-669.
[4]王文.β受体阻滞剂在高血压治疗中的地位和再评价[J].中华高血压杂志,2013,(08):715-718.
[5]冯颖青,李勇,张宇清等.β受体阻滞剂在高血压应用中的专家指导建议[J].中华高血压杂志,2013,(08):719-727.
[6]李露,常静.β受体阻滞剂预防心力衰竭患者心脏性猝死的研究进展[J].重庆医学,2012,1(7):1768-1771.
[7]冯颖青,李勇,张宇清,王浩,陈源源,孙忠实,李悦,王鸿懿,孙宁玲.β受体阻滞剂在高血压应用中的专家指导建议[J].慢性病学杂志,2013,1(1):806-815.
[8]郭艺芳.β受体阻滞剂是否可以常规用于所有冠状动脉性心脏病患者[J].中华高血压杂志,2015,(02):109-114.